PH Health Ltd v. Fresenius Kabi: Ephedrine Sulfate Patent Suit Dismissed Without Prejudice
PH Health Limited filed a patent infringement action against Fresenius Kabi in the Delaware District Court over US10869845B1, a patent covering ephedrine sulfate injection formulations. The case was voluntarily dismissed without prejudice just 88 days after filing, before Fresenius Kabi filed any answer or dispositive motion.
Early exit: PH Health drops ephedrine sulfate suit before Fresenius Kabi responds
PH Health Limited, a pharmaceutical patent holder, filed suit against Fresenius Kabi in the Delaware District Court on August 29, 2025, asserting infringement of US10869845B1. The accused product is Fresenius Kabi’s ephedrine sulfate injection — a 50 mg/10mL single-dose vial. The case was assigned to Judge Jennifer L. Hall and pursued by Heyman Enerio Gattuso & Hirzel, LLP on behalf of the plaintiff.
PH Health voluntarily dismissed the action on November 25, 2025, invoking Rule 41(a)(1)(A) of the Federal Rules of Civil Procedure. This procedural mechanism allows a plaintiff to dismiss as of right — without a court order — where the defendant has not yet served an answer or dispositive motion. The dismissal was explicitly entered without prejudice, meaning PH Health retains the legal ability to refile the same claims against Fresenius Kabi in the future.
The 88-day lifecycle of this case — from complaint to dismissal — is notably short and suggests the dismissal was a deliberate tactical decision rather than a resolution on the merits. The public record does not disclose whether the parties reached any side agreement, licensing discussion, or consent-based resolution. The absence of any defendant filing or court ruling means the substantive merits of the infringement claims against US10869845B1 remain entirely unadjudicated.
Filing to Voluntary dismissal in 88 days
88 days — resolved before defendant’s first responsive pleading
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A): dismissal as of right, no court order needed
Rule 41(a)(1)(A) permits a plaintiff to dismiss an action without a court order at any point before the defendant has served an answer or a motion for summary judgment. PH Health invoked this right explicitly, confirming Fresenius Kabi had not yet filed any responsive pleading. The dismissal takes effect immediately upon filing and requires no judicial approval — it is a unilateral plaintiff decision.
No merits adjudicationWithout prejudice: the claims can be refiled
A dismissal ‘without prejudice’ means the action is terminated but the plaintiff’s underlying legal claims are not extinguished. PH Health could refile the same infringement claims based on US10869845B1 against Fresenius Kabi in a future action, subject to applicable statutes of limitations. The public record does not specify whether any settlement, licence, or other side agreement accompanied the dismissal — that information remains private.
Refiling remains possibleFresenius Kabi escapes this action — but exposure may persist
Fresenius Kabi avoided any adjudication of the infringement allegations and was never required to serve a formal defence in this action. However, because the dismissal is without prejudice, Fresenius Kabi cannot treat this as a final resolution. The patent US10869845B1 remains in force, and the same product — the 50 mg/10mL ephedrine sulfate injection — could be subject to a future action. Monitoring the patent’s status and any related proceedings is advisable.
Ongoing patent riskEphedrine sulfate injections: patent risk not eliminated by early exit
For competitors and market participants in the injectable pharmaceutical sector, this dismissal without prejudice does not clear the IP landscape around ephedrine sulfate formulations. US10869845B1 remains asserted and unadjudicated. Other manufacturers of ephedrine sulfate injections — particularly ANDA filers and generic entrants — should consider the patent’s scope carefully. The early dismissal may signal a strategic recalibration by PH Health rather than an abandonment of enforcement.
IP landscape remains unsettledFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | PH Health Limited | Individual | Pharmaceutical patent holder — asserting US10869845B1 covering ephedrine sulfate injectionSearch in Eureka ↗ |
| Defendant | Fresenius Kabi | Individual | Fresenius Kabi — global pharmaceutical and medical device company; maker of accused ephedrine sulfate injectionSearch in Eureka ↗ |
| Plaintiff counsel | Dominick T. Gattuso | Attorney | Counsel for PH Health LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing PH Health LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice cites Rule 41(a)(1)(A) and confirms the defendant had not yet served an answer or dispositive motion — the precise conditions required for a plaintiff’s unilateral right of dismissal. The explicit ‘without prejudice’ designation is legally significant: no res judicata bar attaches, and the same claims could be reasserted in a future proceeding. The filing effectively terminates this action on procedural grounds with no merits ruling, leaving US10869845B1’s validity and Fresenius Kabi’s alleged infringement entirely unresolved.
US10869845B1 — Ephedrine sulfate injectable formulation
US10869845B1 relates to ephedrine sulfate injection formulations, with the accused product being a 50 mg/10mL single-dose vial. The patent was filed under application number US16/749378. Ephedrine sulfate injections are used clinically as vasopressors — primarily to treat hypotension during anaesthesia. The formulation patent likely covers aspects of the composition, concentration, or preparation method that distinguish it from prior-art ephedrine products.
Vasopressor injectables represent a commercially significant segment of the hospital pharmaceutical market, and single-dose vial presentations have become increasingly preferred due to safety and contamination-risk considerations. A patent covering a differentiated ephedrine sulfate injection format carries meaningful enforcement potential against generic and branded competitors alike. The unadjudicated status of this patent following the dismissal means its claim scope remains untested — elevating the risk profile for any party commercialising comparable formulations.
Should you run an FTO analysis against US10869845B1?
Any company manufacturing, importing, or distributing ephedrine sulfate injection products — particularly in single-dose vial formats at or near 50 mg/10mL — should assess their exposure to US10869845B1. The patent remains in force and its claims are unadjudicated. ANDA filers, contract manufacturers, and hospital-supply distributors in the vasopressor injectable category are most directly at risk and should prioritise a targeted freedom-to-operate review.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US10869845B1 against your product specifications in minutes, identifying claim overlap, prior art, and design-around opportunities. For pharmaceutical R&D and regulatory teams navigating injectable formulation IP, Eureka surfaces related patents, litigation history, and competitor filings in a single workflow — reducing the manual overhead of a traditional FTO review.
Run a freedom-to-operate analysis on US10869845B1 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical injection patent cases in Delaware District Court
Cases involving injectable pharmaceutical formulation patents in the Delaware District Court — including vasopressor and anaesthesia-related drug IP disputes.
What this case signals for the injectable pharmaceutical IP landscape
An early voluntary dismissal in a pharmaceutical patent case rarely signals surrender — it more often reflects a shift in strategy or undisclosed negotiation.
Without-prejudice dismissal keeps litigation leverage intact for PH Health
PH Health’s decision to dismiss before Fresenius Kabi filed any responsive pleading preserves maximum optionality. The company retains the right to refile, negotiate from a position of patent ownership, or pursue other defendants. Competitors in the ephedrine sulfate injection market should not treat this exit as a signal that US10869845B1 is unenforceable.
Generic and ANDA filers in ephedrine sulfate should reassess FTO exposure
The unadjudicated status of US10869845B1 means no court has ruled on its validity or scope. Any company commercialising ephedrine sulfate injection — particularly in single-dose vial formats — carries residual infringement risk. A targeted freedom-to-operate analysis against this patent is warranted before market entry or continued distribution.
Limited v Fresenius — key questions answered
PH Health Limited filed a patent infringement action against Fresenius Kabi in the Delaware District Court on August 29, 2025, asserting US10869845B1 against Fresenius Kabi’s ephedrine sulfate injection (50 mg/10mL). The case was voluntarily dismissed without prejudice on November 25, 2025 — 88 days after filing — before Fresenius Kabi served any answer or dispositive motion.
A dismissal without prejudice means PH Health’s infringement claims were terminated without any ruling on the merits. The patent US10869845B1 remains in force and PH Health retains the legal right to refile the same claims against Fresenius Kabi in a future action. No res judicata bar attaches, and the case does not constitute an adjudication of validity or non-infringement.
US10869845B1 is a US patent relating to ephedrine sulfate injection formulations, filed under application number US16/749378. In this litigation, it was asserted against Fresenius Kabi’s ephedrine sulfate injection product — a 50 mg/10mL single-dose vial used clinically as a vasopressor, primarily to manage hypotension during anaesthesia.
The public record does not disclose the reason for the early dismissal. Early voluntary dismissals in pharmaceutical patent cases can reflect undisclosed licensing negotiations, a strategic decision to refile in a different forum, parallel PTAB or ANDA proceedings, or a reassessment of litigation readiness. No settlement or agreement is confirmed in the public docket.
The dismissal does not limit PH Health’s ability to assert US10869845B1 against other parties. Because the patent’s claims were never adjudicated, other manufacturers of ephedrine sulfate injection products — including ANDA filers and generic suppliers — remain potentially exposed. A freedom-to-operate analysis against this patent is advisable for any company active in this product category.
PatSnap Eureka searches patents and litigation data to answer instantly.